3929 Westpoint Blvd Ste G
Winston Salem, NC, 27103 United States
Who needs organ donation when Tengion's got organ regeneration. The biotechnology company is focused on developing cell therapies to regenerate human tissue and organs. Its lead candidates are a surgically implanted urinary conduit that uses a patient's own cells to catalyze the regrowth of bladder tissue following bladder removal due to cancer and a Neo-Bladder product designed to help patients suffering from spina bifida and spinal cord injuries. Other product candidates target renal, gastrointestinal, and vascular diseases. Believing it can fill a niche among current therapies on the bladder market, Tengion went public in 2010 through a $26 million IPO to help advance its research and development activities.